Travere therapeutics reports first quarter 2023 financial results

Filspari™(sparsentan) granted accelerated approval by fda for the reduction of proteinuria in iga nephropathy (igan) on february 17 th , 2023; commercial launch underway

TVTX Ratings Summary

TVTX Quant Ranking